Yinon Ben-Neriah

This inventor holds 11 USPTO granted patents and 4 published patent applications and 3 EPO patents. Top assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Signal Pharmaceuticals, Inc., Biotheryx, Inc.. Active years: 1999-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yinon Ben-Neriah. Retrieved from https://idiyas.com/inventor/yinon-ben-neriah

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 11 (Patent Applications = 4)

% Patents Active = 45.5

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 14(Granted Patents)

Location History:

Zion, IL (1999 - 2012)
Mevasseret Zion, IL (2005 - 2024)

Company Filing History:

6 out of 917

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

patents

5 out of 169

Signal Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 1999-2024

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12138265 - Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use (2024-11-12),

2. 11999721 - Pyrazole compounds and uses thereof (2024-06-04),

3. 11925641 - Pyrazole pyrimidine derivative and uses thereof (2024-03-12),

4. 11072599 - Pyrazole compounds and uses thereof (2021-07-27),

5. 9623109 - Methods of killing cells and use of same in prevention and treatment of cancer (2017-04-18),

6. 8263326 - Compounds and methods for modulating activation of NF-κB (2012-09-11),

7. 7414120 - Compounds and methods for modulating activation of NF-κB (2008-08-19),

8. 7186503 - Compounds and methods for modulating activation of NF-κB (2007-03-06),

9. 6905836 - Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of iκb (2005-06-14),

10. 6656713 - Compounds and methods for modulating activation of NF-&kgr;B (2003-12-02),

11. 5932425 - Compositions and methods for modulating cellular NF-.kappa.B activation (1999-08-03),

Title: Innovations of Yinon Ben-Neriah

Introduction

Yinon Ben-Neriah is a notable inventor based in Mevasseret Zion, Israel. He has made significant contributions to the field of pharmaceuticals, holding a total of 11 patents. His work focuses on developing compounds that have therapeutic applications in treating various diseases.

Latest Patents

Among his latest patents is a groundbreaking invention related to heteroaryl compounds and their pharmaceutical compositions. This patent outlines methods for treating, ameliorating, or preventing symptoms of disorders mediated by casein kinase 1 (CK1), interleukin-1 receptor associated kinase (IRAK1), or cyclin-dependent kinase 9 (CDK9). Another significant patent involves pyrazole compounds, which are designed for treating malignant diseases and inflammatory disorders.

Career Highlights

Yinon has worked with prominent organizations, including Yissum Research Development Company of the Hebrew University of Jerusalem and Signal Pharmaceuticals, Inc. His experience in these companies has allowed him to advance his research and development efforts in the pharmaceutical industry.

Collaborations

He has collaborated with esteemed colleagues such as Avraham Yaron and Anthony M. Manning, contributing to the advancement of innovative solutions in his field.

Conclusion

Yinon Ben-Neriah's contributions to pharmaceutical innovations demonstrate his commitment to improving health outcomes through his inventions. His extensive patent portfolio reflects his expertise and dedication to research and development in the medical field.

Profile summary based on public USPTO records.